(NASDAQ: SLN) Silence Therapeutics's forecast annual revenue growth rate of 101.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Silence Therapeutics's revenue in 2025 is $27,892,500.On average, 4 Wall Street analysts forecast SLN's revenue for 2025 to be $3,178,125,766, with the lowest SLN revenue forecast at $85,014,510, and the highest SLN revenue forecast at $9,276,499,950. On average, 4 Wall Street analysts forecast SLN's revenue for 2026 to be $3,515,349,989, with the lowest SLN revenue forecast at $1,586,937,520, and the highest SLN revenue forecast at $6,764,321,179.
In 2027, SLN is forecast to generate $39,670,604,183 in revenue, with the lowest revenue forecast at $7,102,962,311 and the highest revenue forecast at $102,953,988,519.